Moderately to Severely Active Ulcerative Colitis Clinical Trials in Guangzhou, Guangdong
2 recruitingGuangzhou, Guangdong, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis
Adult Patients With Moderately to Severely Active Ulcerative Colitis
Guangdong Hengrui Pharmaceutical Co., Ltd20 enrolled1 locationNCT07232576
Recruiting
Phase 3
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Takeda402 enrolled36 locationsNCT03221036